SCHEMBL3223030

SCHEMBL3223030

CN(CC1CCNCC1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.50
SLC18A3 Q16572 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
USP30 Q70CQ3 1/20 0.41
KDM1A O60341 3/20 0.40
MAOB P27338 3/20 0.40
MAOA P21397 2/20 0.40
HRH1 P35367 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
CYP2D6 P10635 1/20 0.40
SCN1A P35498 1/20 0.40
KMT2A Q03164 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
SLC6A4 P31645 4/20 0.39
SLC6A2 P23975 3/20 0.39
KHK P50053 1/20 0.39
HTR3A P46098 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12225935 0.87 PTGIR (0.43) MEN1KMT2A
SCHEMBL2392197 0.83 EP300 (0.38) GBA1SLC6A4SLC6A2KHK
SCHEMBL5406716 0.83 CHRM5 (0.39) GBA1
SCHEMBL15998771 0.81 TRPV1 (0.46) MEN1KMT2A
Hydrochloric Acid SCHEMBL5412255 0.81 CHRM5 (0.38) GBA1
SCHEMBL31381408 0.79 EP300 (0.41) GBA1USP30SLC6A4SLC6A2
SCHEMBL5651526 0.76 GBA1 (0.56) GBA1SIGMAR1USP30MAOBMAOA
SCHEMBL3042636 0.76 ACHE (0.46) GBA1USP30MAOAMEN1KMT2A
SCHEMBL4071618 0.75 HTT (0.46) GBA1USP30MAOBHRH1MEN1
Hydrochloric Acid SCHEMBL8332334 0.74 ACHE (0.45) GBA1USP30MAOAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115776887-A MDM2 degrading agents and uses thereof 凯麦拉医疗公司 2023-03-10 CN disclosed
US-8519139-B2 Indazolamides with analgesic activity Aziende Chimeche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) 2013-08-27 US disclosed
US-8507528-B2 2-alkyl-indazole compounds for the treatment of certain cns-related disorders AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2013-08-13 US disclosed
EP-2099780-B1 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS ACRAF (IT) 2013-01-09 EP disclosed
US-20100056573-A1 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2010-03-04 US disclosed
US-20100048907-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO S.P.A. (IT) 2010-02-25 US disclosed
US-7638534-B2 Use of indazole derivatives for the treatment of neuropathic pain AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2009-12-29 US disclosed
US-7632849-B2 N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)- 1-(1-methylethyl)-1H-indazole-3-carboxamide; antiarthritic agents; rheumatic diseases; osteoarthritis; fibromyaleia;anticarcinogenic agents, pain; neuropathic pain; immunoincompetance; trauma; antiischemic agents; multiple sclerosis AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2009-12-15 US disclosed
EP-2099780-A1 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 2009-09-16 EP disclosed
WO-2008061688-A1 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2008-05-29 WO disclosed
EP-1646387-B1 USE OF INDAZOLE DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN ACRAF (IT) 2006-11-15 EP disclosed
US-20060183775-A1 Use of indazole derivatives for the treatment of neuropathic pain AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO S.P.A. (IT) 2006-08-17 US disclosed
US-20060052417-A1 Indazolamides with analgesic activity AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2006-03-09 US disclosed
EP-1594859-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 2005-11-16 EP disclosed
WO-2004074275-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056573-A1 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS CYP11B2, CYP1A2, INA GBA1 195/4885SLC18A3 385/4885SIGMAR1 1349/4885
US-20060183775-A1 Use of indazole derivatives for the treatment of neuropathic pain SCN3A, OPRD1, SCN1A GBA1 363/4885SLC18A3 632/4885SIGMAR1 32/4885
US-20100048907-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY TRPV1, CA2, TRPV2 GBA1 1348/4885SLC18A3 582/4885SIGMAR1 178/4885
US-20060052417-A1 Indazolamides with analgesic activity P2RX7, P2RX3, P2RX1 GBA1 1354/4885SLC18A3 2681/4885SIGMAR1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.